Top Page
COSMO Pharmaceuticals N.V.
(LSE:COPN)
COSMO Pharmaceuticals N.V. (COPN) vs. iShares MSCI Switzerland ETF (EWL)
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
COSMO Pharmaceuticals N.V. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 266.79M | 92.78M | 102.09M | 65.07M | 60.95M |
| Gross Profit | 246.92M | 53.44M | 83.33M | 49.93M | 50.51M |
| EBITDA | 165.71M | 19.70M | 47.49M | 40.48M | 7.84M |
| Net Income | 133.24M | -4.93M | 17.23M | 21.67M | -7.90M |
Balance Sheet | |||||
| Total Assets | 646.77M | 553.98M | 759.59M | 805.56M | 596.16M |
| Cash, Cash Equivalents and Short-Term Investments | 142.96M | 50.27M | 240.95M | 222.21M | 212.85M |
| Total Debt | 2.20M | 1.84M | 173.60M | 169.92M | 168.14M |
| Total Liabilities | 141.68M | 124.94M | 295.80M | 292.88M | 196.04M |
| Stockholders Equity | 498.33M | 422.16M | 456.93M | 505.28M | 400.13M |
Cash Flow | |||||
| Free Cash Flow | 156.76M | 18.31M | 25.92M | 4.11M | 4.90M |
| Operating Cash Flow | 162.41M | 22.71M | 33.23M | 12.61M | 12.98M |
| Investing Cash Flow | -128.88M | 42.30M | 1.69M | 24.86M | 75.45M |
| Financing Cash Flow | -40.22M | -211.27M | -46.13M | -27.25M | -11.88M |
COSMO Pharmaceuticals N.V. Technical Analysis
COSMO Pharmaceuticals N.V. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | CHF981.64M | 17.82 | 11.46% | 3.29% | -3.44% | -21.64% | |
51 Neutral | $7.83B | -0.15 | -40.10% | 2.29% | 21.46% | -2.01% | |
| ― | $258.90B | 23.84 | 31.98% | 3.43% | ― | ― | |
65 Neutral | CHF566.94M | 7.79 | ― | 58.51% | ― | ||
| ― | $1.16B | ― | -7.82% | ― | ― | ― | |
61 Neutral | CHF1.15B | 282.78 | ― | 7.29% | -112.70% | ||
49 Neutral | CHF436.56M | ― | 4.55% | -2.42% | -222.68% |
COSMO Pharmaceuticals N.V. Corporate Events
Cosmo Pharmaceuticals N.V. has extended its strategic production agreement with Takeda for the global supply of Mesalazine MMX 1200 mg, a medication for ulcerative colitis. This extension reinforces Cosmo’s role as a reliable partner in the pharmaceutical industry, highlighting its manufacturing capabilities and commitment to innovation and sustainability. The agreement aligns with Cosmo’s Vision 2030 strategy to expand its leadership position as a CDMO and strengthen its global partnerships.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals announced that potential US tariffs on Swiss pharmaceutical companies will not impact its operations, as it does not export from Switzerland to the US and has long-term global contracts. The company remains optimistic about its growth trajectory, bolstered by strong fundamentals and increased EBITDA, and continues to deliver stable results to shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals reported strong financial results for the first half of 2025, leading to an increase in EBITDA guidance for the full year by EUR 4.5 million. The company experienced significant growth in recurring revenues, particularly from its GI Genius™ and Winlevi® products, and maintained a solid balance sheet. This performance aligns with Cosmo’s ‘Vision 2030’ strategy, emphasizing growth in AI-driven healthcare and specialty pharmaceuticals. The company anticipates continued momentum in the second half of 2025, with expectations of sustained growth in its key sectors, including MedTech AI and dermatology, which are driven by unmet clinical needs.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals N.V. has launched Winlevi®, a novel acne treatment, in Singapore and Malaysia, marking its first entry into the Southeast Asian market through a partnership with Hyphens Pharma International Limited. This launch represents a significant step in Cosmo’s global expansion strategy, aiming to meet the unmet needs of patients with acne vulgaris, a common skin condition affecting millions worldwide. The collaboration with Hyphens Pharma underscores both companies’ commitment to providing innovative dermatological solutions and expanding their presence in a rapidly growing market.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals has made significant strides in its ESG initiatives, achieving an upgrade in its MSCI ESG rating to ‘A’ and doubling its LSEG ESG score, reflecting its commitment to sustainability. By joining the UN Global Compact and committing to the Science Based Targets Initiative, Cosmo positions itself as a leader in sustainable healthcare, aligning its operations with global standards and attracting ESG-focused investments.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals N.V. unveiled its ambitious vision for 2030 at the Investor Day 2025, aiming for EUR 480 million in recurring revenues and a 40% EBITDA margin. The company plans to leverage AI-driven growth and innovation, focusing on expanding its core business and digital AI platforms. This strategic roadmap is expected to position Cosmo as a significant player in the future of healthcare, creating value for patients, partners, and shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals N.V. has announced the sale of its ‘Digital Trust’ division to Tinexta InfoCert for EUR 8.3 million as part of a strategic move to streamline its portfolio. This transaction aligns with Cosmo’s focus on growth in AI-powered medical devices and therapeutics, aiming to enhance its position as an innovation-driven healthcare company. By reallocating resources to core areas, Cosmo seeks sustainable growth and greater benefits for patients and shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF84.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals N.V. has announced a groundbreaking clinical study to evaluate the integration of its Medtronic GI Genius™ endoscopy module with Apple Vision Pro at Rush University Medical Center. This innovative approach aims to enhance real-time AI-supported insights during colonoscopy procedures, potentially setting a new standard in interventional medicine. The study’s outcomes will support Cosmo’s FDA approval application, marking a significant step in the fusion of clinical AI and spatial computing in endoscopy.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
Cosmo Pharmaceuticals N.V. announced the approval of all agenda items at its 2025 general meeting, with shareholders endorsing a 2.5% increase in dividend distribution to EUR 2.05 per share. This decision reflects the company’s commitment to creating long-term value for its stakeholders, as emphasized by the Board Chairman and CEO. The company also plans to provide further insights into its projects at the upcoming Investor Day in Zurich.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.